Reviewing Livongo Health (NASDAQ:LVGO) & Fresenius Medical Care AG & Co. (NASDAQ:FMS)

Livongo Health (NASDAQ:LVGO) and Fresenius Medical Care AG & Co. (NYSE:FMS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, earnings, dividends and risk.

Dividends

Fresenius Medical Care AG & Co. pays an annual dividend of $0.45 per share and has a dividend yield of 1.3%. Livongo Health does not pay a dividend. Fresenius Medical Care AG & Co. pays out 19.8% of its earnings in the form of a dividend.



Earnings & Valuation

This table compares Livongo Health and Fresenius Medical Care AG & Co.’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Livongo Health $68.43 million 32.93 -$33.38 million N/A N/A
Fresenius Medical Care AG & Co. $19.44 billion 1.08 $2.34 billion $2.27 15.22

Fresenius Medical Care AG & Co. has higher revenue and earnings than Livongo Health.

Profitability

This table compares Livongo Health and Fresenius Medical Care AG & Co.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Livongo Health N/A N/A N/A
Fresenius Medical Care AG & Co. 7.34% 10.18% 4.50%

Institutional & Insider Ownership

1.5% of Fresenius Medical Care AG & Co. shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and price targets for Livongo Health and Fresenius Medical Care AG & Co., as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Livongo Health 0 1 9 0 2.90
Fresenius Medical Care AG & Co. 0 5 4 0 2.44

Livongo Health currently has a consensus price target of $44.20, indicating a potential upside of 85.25%. Fresenius Medical Care AG & Co. has a consensus price target of $56.06, indicating a potential upside of 62.30%. Given Livongo Health’s stronger consensus rating and higher probable upside, research analysts plainly believe Livongo Health is more favorable than Fresenius Medical Care AG & Co..

Summary

Fresenius Medical Care AG & Co. beats Livongo Health on 7 of the 12 factors compared between the two stocks.

About Livongo Health

Livongo Health, Inc. provides an integrated suite of solutions for the healthcare industry in North America. It solutions promote health behavior change based on real-time data capture supported by intuitive devices and insights driven by data science. The company offers a platform that provides cellular-connected devices, supplies, informed coaching, data science-enabled insights, and facilitates access to medications. Its products include Livongo for Diabetes, Livongo for Hypertension, Livongo for Prediabetes and Weight Management, and Livongo for Behavioral Health by myStrength. The company was formerly known as EosHealth, Inc. and changed its name to Livongo Health, Inc. in 2014. Livongo Health, Inc. was incorporated in 2008 and is headquartered in Mountain View, California.

About Fresenius Medical Care AG & Co.

Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems for the treatment of ESRD; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, hospitalist, emergency, intensivist, medical cost management, ambulatory surgery center, health plan, urgent care, physician nephrology and cardiology, and ambulant treatment services. The company sells its products to clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2018, it operated 3,928 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.

Receive News & Ratings for Livongo Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Livongo Health and related companies with MarketBeat.com's FREE daily email newsletter.